Calidi Biotherapeutics, Inc. focuses on developing innovative immunotherapy treatments for cancer, leveraging its proprietary platform for oncolytic virus therapy. The company operates primarily in the United States, with a pipeline that includes candidates targeting various solid tumors, which positions it uniquely in the competitive landscape of biotechnology.
Business Overview
Calidi generates revenue primarily through research grants and collaborations with larger pharmaceutical firms, which provide funding in exchange for access to its proprietary technologies. The company has a competitive advantage due to its unique approach to oncolytic virus therapy, which has shown promise in preclinical studies, potentially allowing for higher pricing power once products reach commercialization.
Progress in clinical trials for its oncolytic virus therapies
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA for new therapies
Market sentiment regarding the biotechnology sector
Risk Factors
Regulatory changes affecting drug approval processes
Technological disruption from competing therapies
Emerging therapies from competitors in the immunotherapy space
Potential for larger pharmaceutical companies to develop similar treatments
High cash burn rate with negative free cash flow
Limited revenue generation leading to reliance on external funding
Macro Sensitivity
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may be impacted during downturns.
Interest rates affect Calidi's financing costs for R&D and clinical trials. Higher rates could increase the cost of capital, impacting future funding and valuations.
minimal - The company has a manageable debt-to-equity ratio of 0.46, indicating limited reliance on credit.
Profile
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, with a 1-year return of -98.0%.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance